First National Daily eMedical Newspaper of India
Nobody Reports News Better Than Us  
We have improved our eMediNexus Platform with a far superior user experience.
Please click here to try it
Editor-in-Chief eMediNexus – Dr KK Aggarwal
Editor-in-Chief eIMANews - Dr Ravi Wankhedkar
14th March, 2018
India sets 2025 as deadline for complete elimination of TB in the country

Dr KK Aggarwal, Recipient of Padma Shri

India has set a target for complete elimination of TB by 2025, before the global target date of 2030 as announced by the Prime Minister Shri Narendra Modi in his inaugural address at the “the Delhi End TB Summit 2018”.

The Prime Minister expressed confidence that the Delhi End TB Summit would be a landmark event towards the complete elimination of TB. He has also asked all Chief Ministers to join in this campaign. In his speech, he acknowledged the role of frontline TB physicians and workers as a crucial part of the drive to eliminate TB and hailed the people afflicted with the disease “those patients who overcome this disease also inspire others”. He called for “multisectoral engagement and interventions” to achieve the desired target (PIB, Prime Minister's Office, March 13, 2018)

The Prime Minister launched Tuberculosis free India campaign on the occasion, to take forward the activities of the National Strategic Plan for Tuberculosis elimination (2017-2025) with its vision of a TB-Free India with zero deaths,.... read more

Top News

Egypt becomes the first country in Eastern Mediterranean region to eliminate lymphatic filariasis

Egypt becomes the first country in the Eastern Mediterranean Region of the World Health Organization (WHO) and the latest in the world to eliminate lymphatic filariasis (LF) as a public health problem. Egypt’s success comes after almost two decades of implementing sustained control and prevention measures (including mass treatment of populations).... read more

Practice Updates

Alirocumab reduces cardiac events after acute coronary syndrome

The proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab was shown to reduce the rates of major adverse cardiovascular events (MACE) by 15% compared with placebo in patients with persistently high cholesterol despite high-intensity statin therapy, according to a study presented March 10, 2018 at the American .... read more

Surgery for obesity improves glycemic control in children with type 2 diabetes

Severely obese adolescents with type 2 diabetes who underwent bariatric surgery had improved their A1c and BMI along with blood pressure, dyslipidemia, and abnormal kidney function compared to those who received either stand-alone metformin, .... read more

Biomarker indicative of untreated major depression

A new imaging study published online February 26, 2018 in the Lancet Psychiatry suggests that higher levels of translocator protein (TSPO) total distribution volume (VT), a marker of microglial activation (inflammation) in the prefrontal cortex, anterior cingulate cortex,.... read more

New ASTRO guideline recommends whole breast irradiation for women with breast cancer

Most women with breast cancer should receive accelerated whole-breast irradiation (WBI) as the standard of care, according to a new guideline from the American Society for Radiation Oncology (ASTRO) published online March 12, 2018 in the journal Practical Radiation Oncology..... read more

Febuxostat and allopurinol similar in terms of cardiovascular outcomes

Febuxostat was similar to allopurinol with respect to rates of adverse cardiovascular events in patients with gout and major cardiovascular coexisting conditions, according to the CARES trial published March 12, 2018 in the New England Journal of Medicine..... read more

Adolescent smoking increases the risk of future psychoses

Adolescents who smoke at least ten cigarettes a day are at a higher risk of psychoses compared to non-smoking young people, according to a study published February 18, 2018 in the journal Acta Psychiatrica Scandinavica..... read more

eMedi Humor
Medicolegal Corner
eMedi Quiz
1.Succinyl CoA.
2. Propionyl CoA.
3. Acetyl CoA.
4. Malonyl CoA.
Lifestyle Updates
Inspirational Story 2: Remember the Small Things
Consult a specialist before switching any medications
Urgent need to take measures to stop marketing same drug under different brands and prices
New Delhi, 13th March 2018: As per a recent study, none of the five most commonly prescribed diabetes pills in India that combine metformin with other medicines have gone through rigorous testing meeting standards laid out by the WHO. In recent years, drug makers have increasingly been blending fixed doses of this medicine with fixed doses of other diabetes drugs that attack the disease differently.
The study, which appeared in BMJ Global Health, noted that the five top-selling fixed dose combination pills in India account for 500 different brands.
The findings of the study are concerning in light of the fact that clinical trials demonstrating safety and efficacy of these fixed dose combinations are neither publicly available or of low quality. It suggests that Indian patients taking these combinations should discuss with their clinicians before making a switching to a different agent.
To Read More or Comment, Click Here